stockrow
Friday 6 November 2026
Export SUPN’s income statement to Excel — free account
Indivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
28.21
0.06
+0.21%
Follow SUPN
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
21.23 | 0.00 | 0.00 | 0.00 | 12.32 | 0.00 | 2.89 | 3.55 | 68.75 | 71.00 |
Piotroski F-Score |
4 | 6 | 3 | 4 | 7 | 3 | 5 | 6 | 7 | 4 |
P/S ratio |
3.62 | 1.38 | 1.94 | 3.36 | 3.18 | 1.66 | 0.48 | 0.98 | 3.63 | 2.42 |
Altman Z-Score |
3.28 | 1.03 | 0.72 | 2.60 | 3.26 | 2.19 | 2.67 | 3.26 | 3.95 | 3.36 |
P/FCF ratio |
0.00 | 328.15 | 0.00 | 0.00 | 7.46 | 0.00 | 2.58 | 3.28 | 16.74 | 6.94 |
Altman Z″-Score (non-manufacturers) |
(0.70) | (1.60) | (1.34) | 3.00 | 5.76 | 4.69 | 6.19 | 6.25 | 4.78 | 2.97 |
Beneish M-Score |
(1.52) | (2.40) | (1.86) | (2.55) | (2.64) | (2.36) | (2.71) | (2.45) | (3.02) | (3.80) |
P/Operating CF |
(20.29) | (96.52) | (7.97) | (167.97) | 15.05 | (15.13) | 9.49 | 11.03 | 63.97 | 20.12 |
P/B ratio |
0.00 | 0.00 | 0.00 | 59.28 | 12.38 | 13.10 | 1.82 | 14.87 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 20.77 | 53.72 | 2.77 | 0.00 | 0.00 | 0.00 |
EV/Sales |
3.72 | 1.39 | 1.78 | 2.63 | 2.09 | 0.70 | (0.56) | 0.30 | 3.28 | 2.27 |
EV/EBITDA |
16.34 | 25.06 | 0.00 | 0.00 | 7.03 | 0.00 | 0.00 | 0.90 | 17.40 | 14.72 |
EV/Operating CF |
(170.70) | 45.94 | (6.50) | (592.63) | 4.68 | (2.33) | (2.94) | 0.99 | 12.15 | 5.89 |
EV/FCF |
(48.52) | 330.75 | (5.52) | (237.05) | 4.90 | (2.26) | (3.02) | 1.00 | 15.13 | 6.52 |
Quick Ratio |
0.49 | 0.66 | 0.51 | 1.10 | 1.64 | 1.74 | 1.69 | 1.53 | 1.37 | 0.92 |
Current Ratio |
0.71 | 0.90 | 0.98 | 1.24 | 1.80 | 1.98 | 1.83 | 1.62 | 1.43 | 0.96 |
Net Debt/EBITDA |
0.44 | 0.20 | 1.19 | 10.20 | (3.66) | 4.80 | (4.00) | (2.06) | (1.85) | (0.96) |
Debt/Assets |
26.56% | 25.30% | 13.64% | 13.57% | 13.21% | 15.28% | 14.35% | 15.58% | 33.38% | 44.25% |
Debt/Equity |
(3.26) | (0.99) | (1.26) | 4.71 | 1.19 | 2.85 | 1.13 | 3.65 | (2.37) | (1.81) |
Asset Turnover |
0.98 | 0.77 | 0.62 | 0.50 | 0.47 | 0.41 | 0.49 | 0.67 | 0.82 | 0.99 |
Operating CF/Net income |
(0.13) | 5.14 | 2.33 | 0.08 | 1.72 | 1.30 | 1.13 | 1.10 | 5.09 | 11.63 |
Capex/Depreciation |
(3.35) | (1.11) | (3.53) | (0.24) | (0.64) | (0.15) | (0.11) | (0.10) | (3.31) | (2.50) |
Interest Coverage |
5.82 | 0.93 | (4.51) | (2.93) | 7.89 | (6.00) | 8.09 | 9.42 | 3.06 | 2.92 |
| (96.33%) | (2.65%) | 182.98% | (41.73%) | 143.86% | (101.72%) | 97.45% | (401.46%) | (23.29%) | (12.20%) | |
| 16.69% | 0.46% | (7.31%) | (2.94%) | 12.19% | (9.30%) | 8.38% | 18.39% | 4.37% | 3.26% | |
ROIC |
629.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(177.97%) | 233.33% | (215.00%) | (18.03%) | 29.37% | (22.84%) | 19.76% | 48.42% | 13.65% | (269.23%) |
Average Days of Receivables |
75.12 | 88.18 | 84.82 | 91.15 | 99.21 | 104.93 | 89.27 | 118.76 | 103.52 | 88.66 |
Research and Development Expense of Revenue |
7.83% | 9.09% | 25.43% | 7.99% | 6.57% | 6.18% | 6.75% | 9.05% | 8.14% | 11.25% |
Selling, General and Administrative Expense of Revenue |
51.17% | 51.52% | 52.06% | 84.68% | 54.49% | 102.94% | 52.74% | 49.15% | 64.68% | 64.56% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 | 0.06 | 0.07 |
Share Based Compensation of Revenue |
2.10% | 2.02% | 1.92% | 1.78% | 1.39% | 1.24% | 0.38% | 1.49% | 1.46% | 0.95% |
Graham Net Nets |
(0.14) | (0.50) | (0.32) | (0.15) | (0.07) | (0.24) | (0.22) | (0.15) | (0.11) | (0.20) |
Graham Number |
0.00 | 0.99 | 5.46 | 0.00 | 6.63 | 0.00 | 5.38 | 4.40 | 0.00 | 0.00 |
Earnings Yield |
4.71% | (0.14%) | (6.12%) | (1.84%) | 8.12% | (14.05%) | 34.62% | 28.15% | 1.45% | 1.41% |
Free Cash Flow Yield |
(2.12%) | 0.30% | (16.66%) | (0.33%) | 13.41% | (18.52%) | 38.71% | 30.46% | 5.98% | 14.40% |
Revenue per Share |
9.91 | 9.00 | 7.98 | 6.48 | 5.43 | 4.41 | 5.38 | 6.91 | 7.58 | 7.35 |
Operating CF per Share |
(0.22) | 0.27 | (2.19) | (0.03) | 2.42 | (1.32) | 1.03 | 2.08 | 2.05 | 2.83 |
Capex per Share |
(0.54) | (0.23) | (0.39) | (0.04) | (0.10) | (0.03) | (0.02) | (0.03) | (0.30) | (0.24) |
Free Cash Flow per Share |
(0.75) | 0.04 | (2.58) | (0.06) | 2.33 | (1.34) | 1.01 | 2.06 | 1.75 | 2.58 |
Cash per Share |
1.56 | 2.42 | 2.99 | 6.42 | 7.57 | 5.85 | 7.26 | 6.35 | 5.98 | 4.81 |
Shareholders Equity per Share |
(0.78) | (2.55) | (1.39) | 0.37 | 1.39 | 0.56 | 1.43 | 0.45 | (1.41) | (2.05) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.78) | (2.55) | (1.39) | 0.37 | 1.39 | 0.56 | 1.43 | 0.45 | (1.41) | (2.05) |
Free Cash Flow |
(94.00) | 5.00 | (353.00) | (9.00) | 339.00 | (197.00) | 148.00 | 299.00 | 252.00 | 372.00 |
Working Capital |
(262.00) | (97.00) | (24.00) | 240.00 | 640.00 | 588.00 | 618.00 | 511.00 | 371.00 | (40.00) |
Capital Expenditures |
(67.00) | (31.00) | (53.00) | (5.00) | (14.00) | (4.00) | (3.00) | (4.00) | (43.00) | (35.00) |
Net Current Asset Value |
(648.00) | (825.00) | (685.00) | (459.00) | (185.00) | (262.00) | (83.00) | (152.00) | (422.00) | (514.00) |
EV/EBIT |
17.59 | 43.52 | 0.00 | 0.00 | 7.76 | 0.00 | 0.00 | 1.02 | 18.58 | 16.10 |
Capex to Sales |
0.05 | 0.03 | 0.05 | 0.01 | 0.02 | 0.01 | 0.00 | 0.00 | 0.04 | 0.03 |
Price to Operating Income |
17.12 | 43.18 | 0.00 | 0.00 | 11.80 | 0.00 | 2.13 | 3.36 | 20.55 | 17.15 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.14 | 0.28 | 0.18 | 0.39 | 0.38 | 0.43 | 0.47 | 0.70 | 0.24 | 0.52 |
Cash ROIC |
(22.60%) | 1.58% | (76.91%) | (0.76%) | 21.91% | (16.78%) | 9.83% | 24.29% | 22.07% | 39.91% |
Accounts Receivable Turnover |
4.57 | 4.39 | 4.56 | 4.10 | 3.95 | 3.42 | 3.03 | 3.16 | 3.86 | 4.57 |
Accounts Payable Turnover |
1.06 | 1.10 | 0.42 | 0.24 | 0.20 | 0.17 | 0.21 | 0.18 | 0.16 | 0.18 |
Inventory Turnover |
1.54 | 1.53 | 1.40 | 1.52 | 1.35 | 1.17 | 1.85 | 1.97 | 2.24 | 2.40 |
Average Days of Payables |
370.94 | 341.30 | 427.93 | 1,416.38 | 2,069.29 | 1,971.75 | 1,624.25 | 2,055.98 | 2,333.89 | 2,244.58 |
Days of Inventory on Hand |
227.01 | 263.87 | 283.19 | 261.70 | 273.03 | 349.95 | 190.32 | 222.42 | 182.50 | 139.86 |
Average Receivables |
271.00 | 270.50 | 239.50 | 220.00 | 200.50 | 189.00 | 259.50 | 318.50 | 283.50 | 231.50 |
Average Payables |
233.00 | 210.00 | 410.50 | 668.50 | 622.00 | 573.50 | 672.00 | 693.00 | 661.50 | 593.00 |
Average Inventory |
160.00 | 151.00 | 124.50 | 104.50 | 94.00 | 83.00 | 75.50 | 65.00 | 46.50 | 44.50 |
Average Assets |
1,258.50 | 1,538.00 | 1,764.50 | 1,800.50 | 1,681.50 | 1,591.50 | 1,599.50 | 1,495.50 | 1,326.50 | 1,073.00 |
Average Common Equity |
(218.00) | (264.50) | (70.50) | 127.00 | 142.50 | 145.50 | 137.50 | (68.50) | (249.00) | (287.00) |
Columns are period end dates · fundamentals updated 2 Nov 2026